Pronounced long-jev-in-ex
The Official Website
Pronounced long-jev-in-ex
The Official Website
December 24, 2010: by Bill Sardi
Las Vegas, NV (Dec. 24, 2010) – In the world’s first comparative microRNA analysis of a resveratrol-based nutriceutical, Longevinex®, a low-dose resveratrol-based dietary supplement, exhibited a distinctive gene regulation pattern apart from plain resveratrol and protected the excised animal heart from damage caused by an experimentally-induced heart attack.
Three weeks of oral resveratrol or Longevinex® ingestion prior to an induced heart attack returned microRNA activity close to their pre-event levels. Among thousands of microRNA’s studied, just six were attributed to exerting the majority of the gene-switching effects measured in the animal heart study — four microRNA optimally regulated by Longevinex® and two optimally by plain resveratrol.
A pre-conditioning effect with resveratrol and Longevinex® had already been demonstrated in prior studies where these small molecules activate antioxidant defenses (nitric oxide, heme oxygenase, adenosine) prior to a heart attack, thus limiting damage in the event of an abrupt halt in the delivery of oxygenated blood to the heart.
This newly published study in the PLoS ONE (Public Library of Science) journal sought to compare and contrast the gene switching pattern for both plain resveratrol and resveratrol in a matrix with other small molecules (Longevinex®) following an induced blockage of circulation in excised animal hearts.
MicroRNA is a mechanism within living cells that switches genes. (For a more complete description of how microRNA works, read here.) MicroRNA’s are short segments of RNA that turn off gene protein-making machinery (called gene expression) when microRNA meshes with messenger RNA.
First thought to exert a minor influence over the human genome (library of genes), microRNA’s are now more fully recognized as “the genome’s guiding hand” – a fundamental regulator of over 90% of human genes. MicroRNA appear to exert a stronger influence over the human genome than two other known mechanisms (methylation and histone modification) of gene regulation. MicroRNAs exceed the biological action of most drugs, which are largely targeted at single genes, while microRNAs regulate complex networks of genes, there is feverish work being done to create drugs that influence microRNA.
Of course, the objective is to produce health benefits, not just switch genes. Indeed, these small molecules did just that. Plain resveratrol and Longevinex® both protected heart tissues and reduced the size of a heart attack, as measured by the amount of scar tissue (fibrosis).
Low-dose Longevinex®, providing 100 mg of trans resveratrol, reduced the size of a heart attack (from ~35% without treatment to ~20% scar tissue with treatment) in a superior manner to plain resveratrol (from ~35% to ~24% scar tissue), and reduced death of heart muscle cells (cardiomyocytes) from ~17% without treatment to ~9% with Longevinex® (48% reduction in cell death), compared to a decline from ~17% to ~12% with plain resveratrol (20% reduction in cell death).
While plain resveratrol modestly improved the pumping pressure of the heart (from ~75 to ~90 millimeters of mercury pressure; 20% improvement), Longevinex® doubled heart pumping pressure (from ~70 to ~140 millimeters of mercury pressure; 100% improvement) compared to no treatment at the two–hour point following an experimentally-induced heart attack.
Also at the two-hour point, Longevinex® improved blood flow in the aorta (first blood vessel outside the pumping side of the heart) from ~15 milliliters per minute without treatment to ~26 milliliters per minute (73% improvement), while resveratrol improved blood flow from ~14 milliliters per minute without treatment to ~21 milliliters per minute (50% improvement).
Upon analysis, it became clear that Longevinex® exerted the greatest influence over the top 25 significantly differentiated microRNA’s in rodent heart tissue. Longevinex® exceeded the effect of resveratrol in 15 of the 25 microRNA’s.
Comparative analysis of three key microRNA (microRNA 20b, 21, 539) are instructive.
Longevinex® profoundly down-regulated microRNA 20b (-1366-fold) compared to plain resveratrol (-189-fold), a microRNA that exerts control over a gene (hypoxia inducing factor, or HIF-1 alpha) that adapts malignant cells to a low oxygen environment. MicroRNA 20b also exhibits control over growth factors (such as vascular endothelial growth factor, aka VEGF). The strong silencing (switching off) of HIF-1 alpha via microRNA 20b would be desirable, for example, to inhibit formation of new blood vessels that feed tumors and which invade the retina at the back of the eyes.
Prior to an induced heart attack, microRNA 21 was tremendously up-regulated (up 391.4-fold) by resveratrol and Longevinex® (up 760.9-fold), was lowered considerably after a heart attack (-4.0), then returned to up-regulation following a heart attack by resveratrol (up 61.5) and Longevinex® (up 59.3), which suggests protective pre-conditioning prior to the event.
MicroRNA 539 exhibited the highest level of up-regulation (214 fold) following a heart attack, which suggests a protective response. Resveratrol diminished this response (down from 214-fold to 172.4 fold) while Longevinex® further enhanced this microRNA response, from 214-fold to 314.6-fold increase. MicroRNA 539 controls of a number of genes involved in healing heart tissue following a heart attack.
The study was performed in the animal laboratory at the National Institutes of Health in Bethesda, Maryland in collaboration with investigators at the NIH’s National Institute on Alcohol Abuse and Alcoholism (NIAAA). The NIAAA’s involvement was predicated upon its mandate to study the effects of alcohol and alcohol-related molecules found in wine, like resveratrol.
The entire report published in PLos One can be viewed here. For further information about Longevinex®, visit www.longevinex.com A slide show that graphically explains this current discovery is located at http://www.longevinex.com/microRNA/
| Superiority Of Longevinex® Over Plain Resveratrol
Induced Heart Attack In Excised Heart Of Rodents Reference: PLoS One December 2010 |
||||
| Measure | Longevinex® | Resveratrol | ||
| After heart attack, no treatment | After heart attack, with Longevinex® | After heart attack, no treatment | After heart attack, with plain resveratrol | |
| Size (area) of heart attack (scar tissue) | 35% | 20% (43% reduction) |
35% | 24% (32% reduction) |
| Pumping pressure of the heart (mm Hg) |
70 | 140 (100% improvement) |
75 | 90 (20% improvement) |
| Blood flow in the aorta (first blood vessel outside the pumping side of the heart) in milliliters per minute | 15 | 26 (73% improvement) |
14 | 21 (50% improvement) |
| Percent die-off of heart muscle cells (apoptosis) | 17% | 9% (48% reduction) |
17% | 12% (20% reduction) |
| Copyright 2010 Resveratrol Partners LLC, dba LONGEVINEX® | ||||
Posted in Longevinex, Resveratrol, Studies
Add comments »